News and Trends 11 Oct 2016 UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies …unabridged antibody counterparts, almost comparable to small peptides. Figure 1. A diagram of a whole antibody – Humabodies whittle these down to just the VH domain reflecting the antibody binding… October 11, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 12 Feb 2018 MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert …those compounds,” he continued. MorphoSys’ first attempt at taking its own antibody to market will be with its blood cancer candidate, MOR208, a monoclonal antibody that targets CD19, which is… February 12, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that… July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Epsilogen completes first clinical trial of IgE antibody to treat cancer …results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target for ovarian cancer. It was… July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Next-Gen Cancer Antibody Technology from Germany enters the Clinic Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie… April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2025 ASCO 2025: key highlights in cancer therapeutics …candidate is also in the clinic for cervical cancer. Another clinical-stage biotech that unveiled data from its cancer immunotherapy trial is Paris-based Enterome. Its candidate EO4010 is made up of… June 4, 2025 - 18 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2017 What Cancer Therapies did European Biotechs Showcase at ASCO 2017? …competitors, BMS, MSD and Roche, in the coveted PD-L1 / PD-1 checkpoint inhibitor space. The Danish antibody giant Genmab presented a Phase I/IIa update on HuMax-AXL-ADC, an antibody-drug conjugate (ADC)… June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Dec 2021 The Billion-Euro European Biotech Companies in 2022 …of antibody treatments for cancer and inflammatory and autoimmune diseases. Its first antibody, Tremfya, a treatment for psoriasis, was launched in 2017 in collaboration with Janssen. The company has ongoing… December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2023 M&As: what’s up with the ADC buying spree? …biotech Orum Therapeutics’ ADC candidate is proof of this. The anti-CD33 antibody-enabled GSPT1 degrader, ORM-6151, received U.S. Food and Drug Administration (FDA) clearance to pursue phase 1 trials for treating… November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2017 French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug …Pharma has in-licensed a new clinical-stage antibody candidate from Novo Nordisk to reinforce its position in the crowded space. In exchange for its anti-C5aR antibody, IPH5401, Novo Nordisk gets a… June 6, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2019 MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II …target of the drug, and MorphoSys, which generated antibody candidates for the target. Several months after the pair reported positive phase I results last year, Novartis licensed the drug in… October 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 10 immunotherapy companies making waves in 2023 …solid tumors. The drug is a monoclonal antibody, which is a type of protein that can bind to antigens of cancer cells; flagging the cells and could trigger the destruction… March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email